肝硬化疾病诊断中生化检验项目价值分析  

Value Analysis of Biochemical Test Items in the Diagnosis of Liver Cirrhosis

作　　者：周冬梅[1] ZHOU Dong-mei(Department of Laboratory Medicine,Second People's Hospital of Jilin,Jilin,Jilin Province,132002 China)

机构地区：[1]吉林省吉林市第二人民医院检验科,吉林吉林132002

出　　处：《系统医学》2020年第24期46-48,共3页Systems Medicine

摘　　要：目的探究肝硬化疾病诊断中生化检验项目的临床应用价值。方法抽取2018年12月-2020年7月期间在该院进行诊治的肝硬化疾病患者(48例)作为研究组,并选取同时期在该院进行体检的健康者(48名)作为参照组,两组实验对象均接受生化检验,对两组受检者的生化检验指标进行对比。结果研究组患者生化检验中的ALT(57.01±4.23)U/L、TBiL(86.12±5.54)μmol/L、TBA(23.23±2.69)μmol/L、AST(94.97±4.14)U/L、PA(106.83±12.77)mg/L、CHE(2130.26±125.65)U/L,与参照组相比,差异有统计学意义(t=63.187、74.306、32.232、102.613、76.015、191.089,P<0.05)。结论肝硬化疾病经过生化检验,其生化检验指标能够为临床诊断提供科学、准确的参考依据,可大力推荐。Objective To explore the clinical application value of biochemical test items in the diagnosis of liver cirrhosis.Methods Selected patients with liver cirrhosis(48 cases)who were diagnosed and treated in the hospital from December 2018 to July 2020 as the research group,and selected healthy people(48 cases)who underwent physical examination in the hospital during the same period as the reference group,both groups of experimental subjects received biochemical tests,and the biochemical test indicators of the two groups of subjects were compared.Results ALT(57.01±4.23)U/L,TBiL(86.12±5.54)μmol/L,TBA(23.23±2.69)μmol/L,AST(94.97±4.14)U/L,PA(106.83±12.77)mg/L,CHE(2130.26±125.65)U/L in the research group were statistically significant compared with the reference group,the difference was statistically significant(t=63.187,74.306,32.232,102.613,76.015,191.089,P<0.05).Conclusion Liver cirrhosis has undergone a biochemical test,and its biochemical test indicators can provide a scientific and accurate reference for clinical diagnosis,which can be strongly recommended.

关 键 词：生化检验 肝硬化疾病 临床诊断 临床指标 参考依据 

分 类 号：R59[医药卫生—内科学]